Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seralutinib Inhalation for Pulmonary Arterial Hypertension
2023-503614-80-00Phase 3Completed
- Sponsor
- GB002, Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Seralutinib inhalation with Placebo inhalation (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to Week 24. Started Nov 2023; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-503614-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503614-80-00.